125 related articles for article (PubMed ID: 37357193)
1. [Clinicopathological and gene mutation characteristics of uterine carcinosarcoma].
Tu J; Xu JZ; Zhang YS; Deng LF
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(24):1864-1867. PubMed ID: 37357193
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.
Chiba Y; Sato S; Itamochi H; Suga Y; Fukagawa T; Oumi N; Oishi T; Harada T; Sugai T; Sugiyama T
Hum Cell; 2017 Apr; 30(2):140-148. PubMed ID: 27889902
[TBL] [Abstract][Full Text] [Related]
3. HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology.
Jenkins TM; Cantrell LA; Stoler MH; Mills AM
Am J Surg Pathol; 2022 Apr; 46(4):435-442. PubMed ID: 35125452
[TBL] [Abstract][Full Text] [Related]
4. [Renal mucinous tubular and spindle cell carcinoma: clinicopathological and whole exome sequencing analyses].
Zou ZG; Wang YH; Zhou JX; Zhan SH; Zheng YS; Liu WS; Yuan X; Guo LC
Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):762-767. PubMed ID: 34405611
[No Abstract] [Full Text] [Related]
5. Exploring biomarkers and prognostic factors in uterine carcinosarcoma: An insight into L1CAM, CDX2, p53, and MSI status.
da Silva JL; de Albuquerque LZ; Rodrigues FR; Bastos NC; Small IA; Barroso EBC; Cordero FL; Fernandes DS; Paulino E; de Melo AC
PLoS One; 2023; 18(5):e0285447. PubMed ID: 37200263
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases.
Jones TE; Pradhan D; Dabbs DJ; Bhargava R; Onisko A; Jones MW
Int J Gynecol Pathol; 2021 Jan; 40(1):84-93. PubMed ID: 31855950
[TBL] [Abstract][Full Text] [Related]
7. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
Matsuzaki S; Klar M; Matsuzaki S; Roman LD; Sood AK; Matsuo K
Gynecol Oncol; 2021 Feb; 160(2):586-601. PubMed ID: 33183764
[TBL] [Abstract][Full Text] [Related]
8. Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-
Xia Y; Wang L; Ma X; Li X
Hum Gene Ther; 2020 Aug; 31(15-16):881-890. PubMed ID: 32013587
[TBL] [Abstract][Full Text] [Related]
9. HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line.
Stockhammer P; Okumus Ö; Hegedus L; Rittler D; Ploenes T; Herold T; Kalbourtzis S; Bankfalvi A; Sucker A; Kimmig R; Aigner C; Hegedus B
Pathol Oncol Res; 2021; 27():636088. PubMed ID: 34257602
[No Abstract] [Full Text] [Related]
10. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
[TBL] [Abstract][Full Text] [Related]
11. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
12. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of EZH2, p16 and p53 expression in uterine carcinosarcomas.
Makk E; Bohonyi N; Oszter A; Éles K; Tornóczky T; Tóth A; Kálmán E; Kovács K
Pathol Oncol Res; 2023; 29():1611547. PubMed ID: 38146588
[No Abstract] [Full Text] [Related]
14. OSucs: An Online Prognostic Biomarker Analysis Tool for Uterine Carcinosarcoma.
An Y; Wang Q; Sun F; Zhang G; Wang F; Zhang L; Li Y; Ren W; Zhu W; Li Y; Ji S; Guo X
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32899312
[TBL] [Abstract][Full Text] [Related]
15. Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma.
Li J; Xing X; Li D; Zhang B; Mutch DG; Hagemann IS; Wang T
Neoplasia; 2017 Feb; 19(2):100-111. PubMed ID: 28088687
[TBL] [Abstract][Full Text] [Related]
16. Does a p53 "Wild-type" Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?
Fadare O; Roma AA; Parkash V; Zheng W; Walavalkar V
Adv Anat Pathol; 2018 Jan; 25(1):61-70. PubMed ID: 28945609
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience.
Erdogan EG; Yalta TD; Can N; Süt N; Taştekin E; Usta U; Puyan FÖ; Usturalı Keskin FE; Kurt BB
Indian J Pathol Microbiol; 2023; 66(3):449-455. PubMed ID: 37530323
[TBL] [Abstract][Full Text] [Related]
18. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
[TBL] [Abstract][Full Text] [Related]
19. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis.
Taylor NP; Zighelboim I; Huettner PC; Powell MA; Gibb RK; Rader JS; Mutch DG; Edmonston TB; Goodfellow PJ
Mod Pathol; 2006 Oct; 19(10):1333-8. PubMed ID: 16810312
[TBL] [Abstract][Full Text] [Related]
20. Uterine carcinosarcoma: A review of the literature.
Cantrell LA; Blank SV; Duska LR
Gynecol Oncol; 2015 Jun; 137(3):581-8. PubMed ID: 25805398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
